» Articles » PMID: 39294194

Location and Function of TDP-43 in Platelets, Alterations in Neurodegenerative Diseases and Arising Considerations for Current Plasma Biobank Protocols

Abstract

The TAR DNA Binding Protein 43 (TDP-43) has been implicated in the pathogenesis of human neurodegenerative diseases and exhibits hallmark neuropathology in amyotrophic lateral sclerosis (ALS). Here, we explore its tractability as a plasma biomarker of disease and describe its localization and possible functions in the cytosol of platelets. Novel TDP-43 immunoassays were developed on three different technical platforms and qualified for specificity, signal-to-noise ratio, detection range, variation, spike recovery and dilution linearity in human plasma samples. Surprisingly, implementation of these assays demonstrated that biobank-archived plasma samples yielded considerable heterogeneity in TDP-43 levels. Importantly, subsequent investigation attributed these differences to variable platelet recovery. Fractionations of fresh blood revealed that ≥ 95% of the TDP-43 in platelet-containing plasma was compartmentalized within the platelet cytosol. We reasoned that this highly concentrated source of TDP-43 comprised an interesting substrate for biochemical analyses. Additional characterization of platelets revealed the presence of the disease-associated phosphoserine 409/410 TDP-43 proteoform and many neuron- and astrocyte-expressed TDP-43 mRNA targets. Considering these striking similarities, we propose that TDP-43 may serve analogous functional roles in platelets and synapses, and that the study of platelet TDP-43 might provide a window into disease-related TDP-43 dyshomeostasis in the central nervous system.

Citing Articles

Development of a Sensitive and Reliable Meso Scale Discovery-Based Electrochemiluminescence Immunoassay to Quantify TDP-43 in Human Biofluids.

An J, Gopalakrishnan L, Ortega V, Saul J, Kadali R, Bowser R Biosensors (Basel). 2024; 14(12).

PMID: 39727843 PMC: 11675039. DOI: 10.3390/bios14120578.


Prion-like Spreading of Disease in TDP-43 Proteinopathies.

Pongracova E, Buratti E, Romano M Brain Sci. 2024; 14(11).

PMID: 39595895 PMC: 11591745. DOI: 10.3390/brainsci14111132.

References
1.
Winkler E, Sengillo J, Sullivan J, Henkel J, Appel S, Zlokovic B . Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 2012; 125(1):111-20. PMC: 3535352. DOI: 10.1007/s00401-012-1039-8. View

2.
Huttlin E, Jedrychowski M, Elias J, Goswami T, Rad R, Beausoleil S . A tissue-specific atlas of mouse protein phosphorylation and expression. Cell. 2010; 143(7):1174-89. PMC: 3035969. DOI: 10.1016/j.cell.2010.12.001. View

3.
Baumgartner R, Umlauf E, Veitinger M, Guterres S, Rappold E, Babeluk R . Identification and validation of platelet low biological variation proteins, superior to GAPDH, actin and tubulin, as tools in clinical proteomics. J Proteomics. 2013; 94:540-51. DOI: 10.1016/j.jprot.2013.10.015. View

4.
Tziortzouda P, Van Den Bosch L, Hirth F . Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci. 2021; 22(4):197-208. DOI: 10.1038/s41583-021-00431-1. View

5.
Buratti E . TDP-43 post-translational modifications in health and disease. Expert Opin Ther Targets. 2018; 22(3):279-293. DOI: 10.1080/14728222.2018.1439923. View